These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33058457)

  • 1. Molecular design aided by random forests and synthesis of potent trypanocidal agents as cruzain inhibitors for Chagas disease treatment.
    de Albuquerque S; Cianni L; de Vita D; Duque C; Gomes ASM; Gomes P; Laughton C; Leitão A; Montanari CA; Montanari R; Ribeiro JFR; da Silva JS; Teixeira C
    Chem Biol Drug Des; 2020 Sep; 96(3):948-960. PubMed ID: 33058457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors.
    Avelar LA; Camilo CD; de Albuquerque S; Fernandes WB; Gonçalez C; Kenny PW; Leitão A; McKerrow JH; Montanari CA; Orozco EV; Ribeiro JF; Rocha JR; Rosini F; Saidel ME
    PLoS Negl Trop Dis; 2015; 9(7):e0003916. PubMed ID: 26173110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.
    Neitz RJ; Bryant C; Chen S; Gut J; Hugo Caselli E; Ponce S; Chowdhury S; Xu H; Arkin MR; Ellman JA; Renslo AR
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4834-4837. PubMed ID: 26144347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation, and structure-activity relationships of potent noncovalent and nonpeptidic cruzain inhibitors as anti-Trypanosoma cruzi agents.
    Ferreira RS; Dessoy MA; Pauli I; Souza ML; Krogh R; Sales AI; Oliva G; Dias LC; Andricopulo AD
    J Med Chem; 2014 Mar; 57(6):2380-92. PubMed ID: 24533839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
    de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
    Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
    Espíndola JW; Cardoso MV; Filho GB; Oliveira E Silva DA; Moreira DR; Bastos TM; Simone CA; Soares MB; Villela FS; Ferreira RS; Castro MC; Pereira VR; Murta SM; Sales Junior PA; Romanha AJ; Leite AC
    Eur J Med Chem; 2015 Aug; 101():818-35. PubMed ID: 26231082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel cruzain inhibitors for the treatment of Chagas' disease.
    Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
    Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, activity, and molecular modeling studies of 1,2,3-triazole derivatives from natural phenylpropanoids as new trypanocidal agents.
    de Souza TB; Caldas IS; Paula FR; Rodrigues CC; Carvalho DT; Dias DF
    Chem Biol Drug Des; 2020 Jan; 95(1):124-129. PubMed ID: 31569301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the Lack of Translation from Cruzain Inhibition to Trypanosoma cruzi Activity with Machine Learning and Chemical Space Analyses.
    Lameiro RF; Montanari CA
    ChemMedChem; 2023 Mar; 18(6):e202200434. PubMed ID: 36692246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Virtual Screening and In Vitro Evaluation of New
    Herrera-Mayorga V; Lara-Ramírez EE; Chacón-Vargas KF; Aguirre-Alvarado C; Rodríguez-Páez L; Alcántara-Farfán V; Cordero-Martínez J; Nogueda-Torres B; Reyes-Espinosa F; Bocanegra-García V; Rivera G
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30970549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
    de Souza ML; de Oliveira Rezende Junior C; Ferreira RS; Espinoza Chávez RM; Ferreira LLG; Slafer BW; Magalhães LG; Krogh R; Oliva G; Cruz FC; Dias LC; Andricopulo AD
    J Chem Inf Model; 2020 Feb; 60(2):1028-1041. PubMed ID: 31765144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential anti-Trypanosoma cruzi Agents.
    Elizondo-Jimenez S; Moreno-Herrera A; Reyes-Olivares R; Dorantes-Gonzalez E; Nogueda-Torres B; Oliveira EAG; Romeiro NC; Lima LM; Palos I; Rivera G
    Med Chem; 2017; 13(2):149-158. PubMed ID: 27396731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay.
    Wiggers HJ; Rocha JR; Fernandes WB; Sesti-Costa R; Carneiro ZA; Cheleski J; da Silva AB; Juliano L; Cezari MH; Silva JS; McKerrow JH; Montanari CA
    PLoS Negl Trop Dis; 2013; 7(8):e2370. PubMed ID: 23991231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.
    Palos I; Lara-Ramirez EE; Lopez-Cedillo JC; Garcia-Perez C; Kashif M; Bocanegra-Garcia V; Nogueda-Torres B; Rivera G
    Molecules; 2017 Jun; 22(6):. PubMed ID: 28629155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
    Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel Inhibitors of Cruzain Cysteine Protease of
    Prates JLB; Lopes JR; Chin CM; Ferreira EI; Dos Santos JL; Scarim CB
    Curr Med Chem; 2024; 31(16):2285-2308. PubMed ID: 37888814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.
    Romeiro NC; Aguirre G; Hernández P; González M; Cerecetto H; Aldana I; Pérez-Silanes S; Monge A; Barreiro EJ; Lima LM
    Bioorg Med Chem; 2009 Jan; 17(2):641-52. PubMed ID: 19110434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
    Moreira DR; Costa SP; Hernandes MZ; Rabello MM; de Oliveira Filho GB; de Melo CM; da Rocha LF; de Simone CA; Ferreira RS; Fradico JR; Meira CS; Guimarães ET; Srivastava RM; Pereira VR; Soares MB; Leite AC
    J Med Chem; 2012 Dec; 55(24):10918-36. PubMed ID: 23167554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
    da Silva EB; Oliveira E Silva DA; Oliveira AR; da Silva Mendes CH; Dos Santos TA; da Silva AC; de Castro MC; Ferreira RS; Moreira DR; Cardoso MV; de Simone CA; Pereira VR; Leite AC
    Eur J Med Chem; 2017 Apr; 130():39-50. PubMed ID: 28242550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.
    Brak K; Kerr ID; Barrett KT; Fuchi N; Debnath M; Ang K; Engel JC; McKerrow JH; Doyle PS; Brinen LS; Ellman JA
    J Med Chem; 2010 Feb; 53(4):1763-73. PubMed ID: 20088534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.